ArticleInternational journal of nanomedicine2012
Liposome-based polymer complex as a novel adjuvant: enhancement of specific antibody production and isotype switch.
Article in International journal of nanomedicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy.Journal of experimental & clinical cancer research : CR · 2023Article
- Review
- Enhanced anticancer activity and endocytic mechanisms by polymeric nanocarriers of n-butylidenephthalide in leukemia cells.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Enhancement of cytotoxicity and induction of apoptosis by cationic nano-liposome formulation ofInternational journal of medical sciences · 2021Article
- Polymeric Nanoparticle-Based Vaccine Adjuvants and Delivery Vehicles.Current topics in microbiology and immunology · 2021Review
- Antitumor Effects ofMolecules (Basel, Switzerland) · 2020Article
- EncapsulatedInternational journal of nanomedicine · 2020Article
- Lipo-PEG-PEI complex as an intracellular transporter for protein therapeutics.International journal of nanomedicine · 2019Article
- Antitumor Effect ofMolecules (Basel, Switzerland) · 2018Article
- Inhibition of breast cancer with transdermal tamoxifen-encapsulated lipoplex.Journal of nanobiotechnology · 2016Article
- Liposomal n-butylidenephthalide protects the drug from oxidation and enhances its antitumor effects in glioblastoma multiforme.International journal of nanomedicine · 2015Article
- Liposomes as vaccine delivery systems: a review of the recent advances.Therapeutic advances in vaccines · 2014Review
- Biomaterials for nanoparticle vaccine delivery systems.Pharmaceutical research · 2014Review
- Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.Journal of the Royal Society, Interface · 2013Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of vaccination is to induce appropriate immunity against pathogens. Antibody-mediated immunity is critical for protection against many virus diseases, although it is becoming more evident that coordinated, multifunctional immune responses lead to the most effective defense. Specific antibody (Ab) isotypes are more efficient at protecting against pathogen invasion in different locations in the body. For example, compared to other Ab isotypes, immunoglobulin (Ig) A provides more protection at mucosal areas. In this study, we developed a cationic lipopolymer (liposome-polyethylene glycol-polyethyleneimine complex [LPPC]) adjuvant that strongly adsorbs antigens or immunomodulators onto its surface to enhance or switch immune responses. The results demonstrate that LPPC enhances uptake ability, surface marker expression, proinflammatory cytokine release, and antigen presentation in mouse phagocytes. In contrast to Freund's adjuvant, LPPC preferentially activates Th1-immunity against antigens in vivo. With lipopolysaccharides or CpG oligodeoxynucleotides, LPPC dramatically enhances the IgA or IgG2A proportion of total Ig, even in hosts that have developed Th2 immunities and high IgG1 serum titers. Taken together, the results demonstrate that the LPPC adjuvant not only increases the immunogenicity of antigens but also modulates host immunity to produce an appropriate Ab isotype by combining with immunomodulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.